Loading...
01/10 17:03
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with revenue growth across multiple segments, improved gross margins, and positive cash flow. The raised guidance for fiscal 2026 and increased adjusted EBITDA outlook further support a positive sentiment. Although some risks were noted, such as competitive pressures and international expansion challenges, the overall outlook and strategic initiatives like the Auryon platform's international traction and positive CPT code changes suggest a favorable stock price movement.
The earnings call revealed strong financial performance, especially in Med Tech, with a 26.1% revenue increase. The company raised guidance for Med Tech, driven by Mechanical Thrombectomy and NanoKnife, indicating confidence in future growth. Despite increased R&D and SG&A expenses, improved operating leverage and profitability were noted. Positive Q&A insights on sales force expansion and clinical trials further support optimism. However, management's reluctance to provide specific metrics for NanoKnife and trial timelines tempers enthusiasm slightly, leading to a positive but not strong positive sentiment.
The earnings call indicates strong financial performance with revenue growth driven by Med Tech and Med Device segments. Positive developments include improved EBITDA and free cash flow, alongside optimistic guidance for Med Tech growth. Although tariffs impacted gross margin, the company is managing these effects. The Q&A reveals confidence in product approvals and growth, particularly for AlphaVac and AngioVac. Despite some ambiguity in management's responses, the overall sentiment is positive with expectations of continued growth, leading to a likely stock price increase of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
